Utah Retirement Systems grew its stake in bluebird bio Inc (NASDAQ:BLUE) by 8.6% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 10,100 shares of the biotechnology company’s stock after buying an additional 800 shares during the quarter. Utah Retirement Systems’ holdings in bluebird bio were worth $1,475,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in BLUE. Stratos Wealth Partners LTD. purchased a new position in shares of bluebird bio in the 3rd quarter valued at about $106,000. NuWave Investment Management LLC boosted its stake in shares of bluebird bio by 10,811.1% in the 3rd quarter. NuWave Investment Management LLC now owns 982 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 973 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of bluebird bio by 635.0% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,154 shares of the biotechnology company’s stock valued at $167,000 after buying an additional 997 shares during the period. Tower Research Capital LLC TRC purchased a new position in shares of bluebird bio in the 2nd quarter valued at about $201,000. Finally, SG Americas Securities LLC purchased a new position in shares of bluebird bio in the 3rd quarter valued at about $214,000.
Several equities research analysts recently weighed in on BLUE shares. Cantor Fitzgerald set a $122.00 target price on bluebird bio and gave the stock a “sell” rating in a research note on Thursday, August 23rd. William Blair restated a “buy” rating on shares of bluebird bio in a research note on Wednesday, September 5th. BidaskClub cut bluebird bio from a “hold” rating to a “sell” rating in a research note on Tuesday, September 11th. Guggenheim started coverage on bluebird bio in a research note on Monday, September 17th. They set a “neutral” rating for the company. Finally, ValuEngine cut bluebird bio from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 17th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and seventeen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $194.80.
BLUE opened at $102.23 on Friday. The company has a market cap of $5.95 billion, a price-to-earnings ratio of -13.26 and a beta of 2.37. bluebird bio Inc has a 52 week low of $100.99 and a 52 week high of $236.17.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Thursday, November 1st. The biotechnology company reported ($2.73) EPS for the quarter, topping the consensus estimate of ($2.90) by $0.17. The company had revenue of $11.50 million for the quarter, compared to analyst estimates of $6.90 million. bluebird bio had a negative return on equity of 31.50% and a negative net margin of 1,326.02%. The firm’s revenue was up 49.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.73) earnings per share. Equities analysts expect that bluebird bio Inc will post -10.71 EPS for the current year.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
See Also: Derivative
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.